Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bioasis Technologies Inc. (BIOAF : OTC)

• Company Description    biOasis Technologies Inc. is a biopharmaceutical company. It is focused on developing and commercializing proprietary pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The Company is engaged in the development of a vector (Transcend) for the transport of therapeutic agents across the blood brain barrier and the development of an in vitro diagnostic assay to assist physicians in diagnosis of Alzheimer's disease (Cognitest). biOasis Technologies Inc. is headquartered in Vancouver, Canada. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.00 Daily Weekly Monthly 20 Day Moving Average: 125 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 0.73 52 Week High: $0.01 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% -3.74% 12 Week -50.00% -57.94% Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 157 Church Street 19th floor - New Haven,CT 06510 USA ph: 203-533-7082 fax: - investors@bioasis.us http://www.bioasis.us

• General Corporate Information    Officers Deborah Rathjen - Executive Chairman Dave Jenkins - Chief Financial Officer John E. Curran - Director John Hemeon - Director Mario Saltarelli - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 09064N103 SIC: 5122 Fiscal Year Fiscal Year End: February Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: 0.73 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 05/31/25 - - 02/28/25 - - 11/30/24 - - ROA 05/31/25 - - 02/28/25 - - 11/30/24 - - Current Ratio 05/31/25 - - 02/28/25 - - 11/30/24 - - Quick Ratio 05/31/25 - - 02/28/25 - - 11/30/24 - - Operating Margin 05/31/25 - - 02/28/25 - - 11/30/24 - - Net Margin 05/31/25 - - 02/28/25 - - 11/30/24 - - Pre-Tax Margin 05/31/25 - - 02/28/25 - - 11/30/24 - - Book Value 05/31/25 - - 02/28/25 - - 11/30/24 - - Inventory Turnover 05/31/25 - - 02/28/25 - - 11/30/24 - - Debt-to-Equity 05/31/25 - - 02/28/25 - - 11/30/24 - - Debt-to-Capital 05/31/25 - - 02/28/25 - - 11/30/24 - -

Powered by Zacks Investment Research ©